New 3′-azido-3′-deoxythymidin-5′-yl O-(ω-hydroxyalkyl) carbonate prodrugs: Synthesis and anti-HIV evaluation

Journal of Medicinal Chemistry

Volumn 44, Issue 5, 2001, Pages 777-786

  Vlieghe, P ^a,b,c   Bihel, F ^a,c   Clerc, T ^b   Pannecouque, C ^d   Witvrouw, M ^d   De Clercq, E ^d   Salles, J P ^b   Chermann, J C ^c   Kraus, J L ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Laboratoire LAPHAL   (France)

^c INSERM   (France)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3' AZIDO 3' DEOXYTHYMIDIN 5' YL O (4 HYDROXYBUTYL)CARBONATE; ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ZIDOVUDINE DERIVATIVE; 3'-AZIDO-3'-DEOXYTHYMIDIN-5'-YL O-(4-HYDROXYBUTYL)CARBONATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; DRUG DERIVATIVE; PRODRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG EFFECT; DRUG STABILITY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

ANTI-HIV AGENTS; CARBAMATES; CELL LINE; DRUG STABILITY; HIV-1; HUMANS; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; ZIDOVUDINE;

EID: 0035263608     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001033s     Document Type: Article

References (55)

1. Isolation of a T-lymphotropic retrovirus from a patient at risk for Acquired Immune-Deficiency Syndrome (AIDS)
2. A new type of retrovirus isolated from patients presenting with lymphadenopathy and AIDS: Structural and antigenic relatedness with equine infectious anemia virus
3. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk of AIDS
4. Retroviral etiology of the acquired immune deficiency syndrome (AIDS)
5. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus, type III/lymphadenopathy-associated virus (HTLV III/LAV) by 2′,3′-dideoxynucleosides
6. In search of a selective antiviral chemotherapy
7. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with HIV reverse transcriptase
8. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro
9. Nucleoside and nonnucleoside reverse transcriptase inhibitors active against HIV
10. HIV reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogues
11. 3′-azido-3′-deoxythymidine (BWA509U): An agent that inhibits the infectivity and cytopathic effect of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in vitro
12. Anti-retroviral therapy of AIDS and related disorders: General principles and specific development of dideoxynucleotides
13. Effects of zidovudine in 365 consecutive patients with AIDS of AIDS-related complex
14. The anti-HTLV III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: A comparison with their parental 2′,3′-dideoxyribonucleosides
15. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity
16. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity
17. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro
18. An efficient asymmetric approach to carbocyclic nucleosides: Asymmetric synthesis of 1592U89, a potent inhibitor of HIV reverse transcriptase
19. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
20. Inhibition of HIV-1 reverse transcriptase and virus replication by a non nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine)
21. Bis(heteroaryl)piperazine(BHAP) reverse transcriptase inhibitors: Structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino] pyridinyl]piperazine monomethane sulfonate (U-90152S), a second-generation clinical candidate
22. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
23. The role of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
24. 2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold
25. Amprenavir approved for HIV treatment
26. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
27. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double blind, placebo-controlled trial
28. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double blind, placebo-controlled trial
29. Synthesis and in vitro activity of long chain 5′-O-[(alkoxycarbonyl)phosphinyl]-3′-azido-3′- deoxythymidines against wild-type and AZT- and forscarnet-resistant strains of HIV-1
30. Optimization of the reaction conditions for the synthesis of neoglycoprotein-AZT-monophosphate conjugates
31. Synthesis of phosphodiester and triester derivatives of AZT with tethered N-methyl piperazine and N,N,N′-trimethylethylenediamine
32. Lipophilic glycosyl phosphotriester derivatives AZT: Synthesis, NMR, transmembrane transport study, and antiviral activity
33. Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-VIH-1 activity
34. A new class of anti-HIV agents: Synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor
35. New bicyclam-AZT conjugates: Design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor
36. Peptide-nucleoside conjugates: Synthesis and anti-HIV activities
37. Synthesis and biological evaluation of prodrugs of zidovudine
38. Brain targeting of anti-HIV nucleosides: Synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine
39. Synthesis, in vitro kinetics, and in vivo studies on protein conjugates of AZT: Evaluation as a transport system to increase brain delivery
40. Mononucleoside phosphodiester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting group: Intercellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate
41. Nucleotide delivery from cyclosaligenyl-3′-azido-3′-deoxythymidine monophosphates (cyclosal-AZTMP)
42. The presence on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship
43. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine
44. Convenient one-pot synthesis of cysteine-containing peptides using the trimethylsilyl chloride-dimethyl sulfoxide/trifluoroacetic acid system and its application to the synthesis of bifunctional anti-HIV compounds
45. Protection for carboxyl group
46. Alkylglycoside carbonates of 3′-azido-3′-deoxythymidine
47. Nitroxide-catalyzed oxidation of alcohols using meta-chloroperbenzoic acid, a new method
48. 3′-Azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human-erythrocytes and lymphocytes by non facilitated diffusion
49. Prodrugs and drug delivery systems
50. A study of the substrate and inhibitor specificities of AMP aminohydrolase, 5′-nucleotidase, and adenylate kinase with adenosine carboxylates of variable chain length
51. The parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics
52. Detection and titration of neutralizing antibodies to HIV using an inhibition of the cytopathic effect of the virus on MT4 cells
53. + cells by selected HIV strains is not inhibited by anti-CD4 monoclonal antibodies
54. Dimethyl sulfoxide and related polar compounds enhance infection of human T cells with HIV-1 in vitro
55. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates